Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Paper under review (10.4161/rna.20091)
    The article is a narrative review describing how microRNAs and RNA-binding proteins influence glucose and lipid homeostasis, and how dysregulation contributes to type 2 diabetes/obesity; it emphasizes tissue-specific targeting challenges and the need for better validation beyond target predictions.



     Long Explanation


    Post-transcriptional regulation in metabolic diseases (10.4161/rna.20091) β€” rigorous review/critique

    What the paper is (and isn’t)
    • Narrative review (no new primary experiments; no participants/subjects enrolled), synthesizing published evidence up to the review’s scope window.
    • Central emphasis: microRNAs and RNA-binding proteins as regulators of glucose and lipid homeostasis in metabolic disease contexts.

    1) Visual map: regulatory layers claimed by the review

    Notes on evidence: This visualization reflects only the explicit examples and output categories mentioned in the provided extract for 10.4161/rna.20091.

    2) What’s well-supported vs what’s uncertain

    More strongly supported (based on the review’s stated synthesis)
    • Post-transcriptional regulation is presented as a mechanistic axis affecting both insulin secretion and insulin signaling, and also contributing to lipid metabolism in metabolic tissues.
    • The review flags translation to therapy/biomarkers as constrained by delivery and tissue-specific targeting, i.e., even if mechanistic links exist, interventions may be hard to deploy broadly and specifically.
    Key uncertainties / failure modes to watch
    • Narrative-review risk: conclusions can be sensitive to which studies are emphasized (selection bias, uneven evidence strength).
    • Prediction-to-causality gap: miRNA/RBP target inference can overcall regulatory relationships if not validated broadly in relevant tissue contexts; the review explicitly notes reliance on predictive/variable-in-vivo evidence within its synthesis.
    • Network context: post-transcriptional regulation is highly context-dependent (cell type, metabolic state, compensatory pathways), so broad claims may not generalize without isoform-, tissue-, and time-resolution. This is consistent with the review’s highlighted focus on tissue-specific networks and translation challenges.

    3) Focused mechanistic critique (skeptical lens)

    A. What would strengthen the field beyond this review?
    • Cross-tissue validation: Mechanistic claims about glucose/lipid homeostasis should be tested in the relevant insulin-sensitive tissues used to generate the hypothesis, not only in surrogate cell lines. (The review’s own limitation notes limited in vivo validation across tissues.)
    • Target specificity: Demonstrations that a miRNA/RBP acts via a defined set of direct targets (rather than indirect downstream effects) reduce the prediction-to-causality gap noted by the review.
    • Temporal resolution: Metabolic phenotypes evolve over time; post-transcriptional regulators can have fast and slow effects. The review (as described) does not substitute for time-resolved, mechanistic experiments.

    4) Quick β€œevidence checklist” for a BGPT user (how to interrogate claims)

    Claim type (from review) What to verify in primary literature Red-flag patterns
    miRNA/RBP β†’ direct target regulation Direct binding/association + functional rescue in relevant tissue/cell type Target predicted only; correlation without direct manipulation
    Regulation β†’ insulin secretion/signaling Causal experiments with pathway-level readouts Phenotypes inferred from altered expression without pathway control
    Regulation β†’ lipid metabolism Mechanistic links in hepatocytes/adipocytes/insulin-sensitive tissues Cell line overexpression artifacts; species/model mismatch

    Run an AI Scientist to strengthen this review

    The provided inputs include only a high-level extract for 10.4161/rna.20091; to produce a substantially deeper, citation-rich critique (covering each claimed mechanism, evidence strength, and study-level counterpoints), run the BGPT agent so it can retrieve and analyze the relevant full-text evidence.

    EVOLVE



    Feedback:    

    Updated: April 24, 2026

     BGPT Paper Review


    Study Novelty

    30%

    As described in the provided extract, this is a comprehensive narrative review that synthesizes known post-transcriptional regulator classes (miRNAs and RBPs) in metabolic disease; it is not presented as introducing new primary mechanisms or datasets.


    Scientific Quality

    60%

    Quality is limited by the inherent constraints of narrative review methodology (selection/coverage bias) and by reliance on heterogeneous model systems and prediction/association-heavy evidence emphasized as potential gaps in the provided extract.


    Study Generality

    70%

    The paper is general across metabolic disease biology by organizing many post-transcriptional regulators into insulin secretion/signaling and lipid metabolism themes, but still constrained by time scope and by the review’s narrative nature.


    Study Usefulness

    70%

    Useful as a structured entry point to candidate regulators (explicit examples provided) and as a reminder of translation bottlenecks (delivery/tissue specificity).


    Study Reproducibility

    40%

    Because it is a narrative review with no new methods/data and because the provided extract does not specify a systematic protocol or deposited analysis artifacts, exact reproducibility of the review’s conclusions cannot be checked from the extract alone.


    Explanatory Depth

    60%

    The extract indicates mechanism-level themes (insulin secretion/signaling, lipid metabolism) but does not provide mechanistic detail per regulator sufficient (from the extract alone) to assess depth across pathways.

     Top Data Sources ExportMCP


     Analysis Wizard



    Integrate miRNA/RBP target predictions with pathway annotations for the review’s named examples, then rank candidates by cross-tissue consistency using available interaction/UTR features from cited datasets.



     Hypothesis Graveyard


    A strongman hypothesis that β€œone miRNA per metabolic phenotype” explains disease is unlikely because the review frames coordinated multi-regulator control and highlights context/tissue specificity and delivery constraints.


    Another strongman hypothesis that predicted miRNA/RBP targets automatically reflect functional regulation in vivo is unlikely given the review’s explicit concern about reliance on predictive frameworks and limited in vivo validation across tissues.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending